News

A new study provides public health planning authorities with a method of calculating the number of COVID-19 isolation beds they would need for people experiencing homelessness based on level of infection in the city. The research holds promise for controlling spread of the virus – or future infectious diseases – in a population that is highly vulnerable and less likely than many others to access health care services.

This month, hundreds of graduating College of Natural Sciences students will walk across a small outdoor stage, masked and socially distanced, and smile at the camera for friends and family mostly watching online.

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of vaccines to protect against variants of the virus or future emerging coronaviruses.

In high school, Brett Dolotina looked forward to a diverse, lively campus culture at UT Austin. Austin seemed like a place where people could live freely. Dolotina, who uses they/them pronouns, looked forward to developing their own identity. Dolotina graduates this month as a Public Health and Biochemistry double major and a passionate student leader, with hopes of building a career in research.

Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures.

In a major boost to efforts to combat COVID-19 globally, a vaccine that recently entered human trials in Vietnam and Thailand, and is slated for a clinical study in Brazil, holds promise for affordable vaccine manufacturing in countries currently dependent on imported vaccines. The vaccine is the result of a partnership between The University of Texas at Austin, the Icahn School of Medicine at Mount Sinai in New York and global partners interested in advancing the supply of affordable vaccines to address the pandemic.

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated. The journal Emerging Infectious Diseases, which has published an early-release version of the study, provides evidence that the coronavirus variant B117 (501Y) had spread across the globe undetected for months when scientists discovered it.

Neuroscience researchers often face challenges when using high-powered microscopes to capture clear images of brain tissue. Microscopes suffer from what researchers call the "eternal triangle of compromise" — image resolution, the intensity of the illumination the sample is subjected to, and speed compete with each other. For example, taking an image of the sample very quickly can result in a dark image, but subjecting a biological sample to more intense light can damage it.

Richard Taylor, clinical assistant professor in the School of Human Ecology, co-authored a study published in Frontiers in Public Health which estimated that 1.7 million vaccine doses are needed to reach herd immunity for COVID-19 in Travis County. A new model could help public health officials in Central Texas better manage what amounts to a much larger vaccination campaign than was carried out during the last pandemic.